Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers a full range of anti-ADAM9 recombinant antibodies with excellent performance to ensure global customers’ projects execute smoothly.
ADAM9 (A Disintegrin and Metalloprotease 9) is a crucial membrane-anchored protein implicated in multiple physiological processes. Increasing evidence demonstrated that elevated ADAM9 expression has been linked to numerous cancers, often associated with increased tumor aggressiveness and poor patient outcomes. Moreover, ADAM9 promotes tumor progression, resistance to therapies, and tumor metastasis through proteolytic or non-proteolytic processes. Given its significant role in oncogenesis, the development of targeted therapies against ADAM9 is paramount for advancing cancer treatment.
ADAM Metallopeptidase Domain 9; A Disintegrin And Metalloproteinase Domain 9; ADAM 9; Meltrin-gamma; Cellular disintegrin-related protein; Metalloprotease/disintegrin/cysteine-rich protein 9; Mltng; MDC9; KIAA0021; CORD9; Cone Rod Dystrophy 9; MCMP; Myeloma cell metalloproteinase.
Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins
Membrane, Secreted (different isoforms)
Cell type enhanced (Pancreatic endocrine cells)
Immune cell enhanced (classical monocyte)
Low cell line specificity
Interacts with SH3GL2 and SNX9 through its cytoplasmic tail (PubMed:10531379). Interacts with ITGA6.
Hydrolase, Metalloprotease, Protease
Based on our robust platform, we develop and provide multiple types of premium anti-ADAM9 recombinant antibody products for customers to select for their significant projects. We are dedicated to providing top-notch research tools and unmatched technical assistance to help our customers make breakthrough discoveries and achieve their scientific objectives easily and efficiently.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-0551CL | Mouse Anti-ADAM9 Recombinant Antibody | Human | Mouse IgG | ELISA, IP, FuncS |
HPAB-N0314-YC | Human Anti-ADAM9 Recombinant Antibody | Human, Cynomolgus monkey | Human IgG | ELISA, FC, IHC |
VS-0723-WK185 | Rabbit Anti-ADAM9 Recombinant Antibody | Human | Rabbit IgG | ELISA, FC |
HPAB-N0314-YC-F(E) | Human Anti-ADAM9 Recombinant Antibody; Fab Fragment | Human, Cynomolgus monkey | Human Fab | ELISA, FC, IHC |
HPAB-N0314-YC-S(P) | Human Anti-ADAM9 Recombinant Antibody; scFv Fragment | Human, Cynomolgus monkey | Human scFv | ELISA, FC, IHC |
We are dedicated to empowering the biopharmaceutical industry by driving research and development forward with world-class product quality and exceptional customer support. By adhering to a stringent quality management system, we ensure our products exceed industry benchmarks. This not only facilitates a more efficient drug development process but also delivers outstanding value to our clients, ensuring their satisfaction and success.
Leveraging our cutting-edge mammalian cell expression platform, which operates entirely serum-free, we offer comprehensive services from gene synthesis to the production of antibodies. This enables us to deliver scalable, high-quality anti-ADAM9 recombinant antibodies to global customers. With over five years of expertise in optimizing processes, we guarantee a rapid and economical supply of antibodies in diverse quantities, ensuring quick turnaround times to meet your needs efficiently.
Featured Anti-ADAM9 Recombinant Antibody Production Platforms
Fig.1 Milligram-scale anti-ADAM9 recombinant antibody production.
Fig.2 Gram-scale anti-ADAM9 recombinant antibody production.
Creative Biolabs is committed to offering premium recombinant antibodies with diverse formats such as Fab, scFv, Diabody, etc., to support global customers swiftly reaching your research purposes. Our wealth of experience and expertise in antibody engineering empower us to customize antibody production to your unique requirements.
Fig.3 Full-Length Anti-ADAM9 Recombinant Antibody Production and Modalities
Table 1. ADAM9-targeted drug information.
Company | Highest Phase | Drug Type | Condition |
ImmunoGen (Originator) MacroGenics |
Phase I | Drug Conjugates |
Cancer, colorectal Cancer, esophagus Cancer, lung (non-small cell) (NSCLC) Cancer, pancreas Cancer, solid tumor Cancer, stomach Triple negative breast cancer |
MacroGenics (Originator) | Preclinical | Biologics |
Cancer, colon Cancer, lung |
ImmunoGen (Originator) | Biological Testing | Drug Conjugates | Cancer |
China Medical University (CMU) DCB-USA |
Biological Testing | Small Molecules (>500 - 750 Da) | Cancer |
ImmunoGen (Originator) MacroGenics (Originator) |
Biological Testing | Drug Conjugates | Cancer |
MacroGenics (Originator) | Biological Testing | Biologics | Cancer |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
For additional information regarding our anti-ADAM9 recombinant antibody offerings, please feel free to get in touch with us.